ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,702.55
-0.19%
Dow Jones
42,063.36
0.09%
US Dollar vs MXN
19.4148
0.00%
Brent Oil
74.135
0.00%
Bitcoin
63,188.99
-0.30%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Rubius Therapeutics Inc (RUBY)

  7. Rubius Therapeutics Inc (RUBY) Noticias

RUBY

Rubius Therapeutics (RUBY)

Rubius Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RUBY
FechaHoraFuenteTítuloSímboloCompañía
10/04/202308:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:RUBYRubius Therapeutics Inc
09/03/202306:33Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:RUBYRubius Therapeutics Inc
02/03/202307:43Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:RUBYRubius Therapeutics Inc
27/02/202307:23Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:RUBYRubius Therapeutics Inc
27/02/202306:37Edgar (US Regulatory)Annual Report (10-k)NASDAQ:RUBYRubius Therapeutics Inc
27/02/202305:52Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:RUBYRubius Therapeutics Inc
22/02/202305:46Edgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:RUBYRubius Therapeutics Inc
22/02/202305:42Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RUBYRubius Therapeutics Inc
02/11/202215:01GlobeNewswire Inc.Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership ChangesNASDAQ:RUBYRubius Therapeutics Inc
19/09/202207:00GlobeNewswire Inc.Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceNASDAQ:RUBYRubius Therapeutics Inc
15/09/202223:20TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND), Rubius Therapeutics (RUBY) and Connect Biopharma Holdings (CNTB)NASDAQ:RUBYRubius Therapeutics Inc
13/09/202206:00GlobeNewswire Inc.Rubius Therapeutics Announces Strategic UpdateNASDAQ:RUBYRubius Therapeutics Inc
12/09/202215:30GlobeNewswire Inc.Rubius Therapeutics to Provide Strategic UpdateNASDAQ:RUBYRubius Therapeutics Inc
09/09/202211:40TipRanksAnalysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Palatin Technologies (PTN) and Rubius Therapeutics (RUBY)NASDAQ:RUBYRubius Therapeutics Inc
12/08/202214:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RUBYRubius Therapeutics Inc
09/08/202211:35TipRanksSVB Securities Keeps Their Hold Rating on Rubius Therapeutics (RUBY)NASDAQ:RUBYRubius Therapeutics Inc
09/08/202207:18Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RUBYRubius Therapeutics Inc
09/08/202207:00GlobeNewswire Inc.Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:RUBYRubius Therapeutics Inc
26/07/202207:00GlobeNewswire Inc.Rubius Therapeutics to Announce Second Quarter 2022 Financial ResultsNASDAQ:RUBYRubius Therapeutics Inc
19/07/202216:54Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:RUBYRubius Therapeutics Inc
19/07/202206:00PR Newswire (US)HotSpot Therapeutics Appoints Jose Carmona to Board of DirectorsNASDAQ:RUBYRubius Therapeutics Inc
14/07/202207:00GlobeNewswire Inc.Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of DirectorsNASDAQ:RUBYRubius Therapeutics Inc
22/06/202207:00GlobeNewswire Inc.Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual MeetingNASDAQ:RUBYRubius Therapeutics Inc
22/06/202205:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:RUBYRubius Therapeutics Inc
08/06/202215:08Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:RUBYRubius Therapeutics Inc
01/06/202207:00GlobeNewswire Inc.Rubius Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:RUBYRubius Therapeutics Inc
26/05/202216:00GlobeNewswire Inc.Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual MeetingNASDAQ:RUBYRubius Therapeutics Inc
24/05/202207:00GlobeNewswire Inc.Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of DirectorsNASDAQ:RUBYRubius Therapeutics Inc
11/05/202205:27TipRanksH.C. Wainwright Remains a Buy on Rubius Therapeutics (RUBY)NASDAQ:RUBYRubius Therapeutics Inc
10/05/202211:38TipRanksRubius Therapeutics (RUBY) Gets a Hold Rating from SVB SecuritiesNASDAQ:RUBYRubius Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RUBY

Su Consulta Reciente

CCOM
SILVER
SILVER
USOTC
BNPQY
BNP Paribas (QX)
CCOM
US500
US 500
NYSE
XOM
Exxon Mobil
CCOM
OILBRENT
Brent Oil
COIN
AVAXUSD
Avalanche
NASDAQ
MSFT
Microsoft
COIN
DOGEUSD
Dogecoin
NYSE
MCD
McDonalds
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
NASDAQ
GOOGL
Alphabet
AMEX
XLF
Financial Select Sector
NYSE
BAC
Bank of America
COIN
XRPUSD
Ripple
FX
USDMXN
US Dollar vs MXN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados